| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1764 |
| Trial ID | NCT03241940 |
| Disease | Recurrent Adult Acute Lymphocytic Leukemia | Acute Lymphoblastic Leukemia | Childhood B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies |
| Year | 2017 |
| Country | United States |
| Company sponsor | Stanford University |
| Other ID(s) | IRB-41383|NCI-2017-01415|PEDSCCT5007|IRB-41383 |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||